Free tool
FAERS Monitor: Oxtellar Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202810 or its brand name (Oxtellar Xr, Oxcarbazepine). Reports on generic versions are filed under their own applications.
Reports
16,581
Serious
12,698
77% of reports
Hospitalization
5,075
Death reported
1,331
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,999
- seizure1,461
- off label use1,157
- fatigue860
- somnolence793
- hyponatraemia746
- dizziness727
- headache715
- drug interaction701
- fall628
- nausea594
- anxiety514
- rash504
- completed suicide503
- balance disorder499
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 64 |
| 2005 | 93 |
| 2006 | 115 |
| 2007 | 94 |
| 2008 | 208 |
| 2009 | 332 |
| 2010 | 301 |
| 2011 | 378 |
| 2012 | 459 |
| 2013 | 434 |
| 2014 | 438 |
| 2015 | 671 |
| 2016 | 887 |
| 2017 | 894 |
| 2018 | 1,017 |
| 2019 | 1,172 |
| 2020 | 1,556 |
| 2021 | 1,317 |
| 2022 | 1,208 |
| 2023 | 1,308 |
| 2024 | 1,284 |
| 2025 | 1,337 |
| 2026 | 1,011 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,578 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyponatraemiaSignal | 746 | 17.0 | 15.9 | 11,110 |
| seizureSignal | 1,461 | 16.2 | 15.5 | 20,725 |
| completed suicideSignal | 503 | 7.7 | 7.1 | 2,918 |
| balance disorderSignal | 499 | 7.4 | 6.7 | 2,731 |
| drug interactionSignal | 701 | 5.6 | 5.2 | 2,670 |
| somnolenceSignal | 793 | 5.0 | 4.7 | 2,557 |
| fallSignal | 628 | 2.4 | 2.2 | 517 |
| anxietySignal | 514 | 2.3 | 2.1 | 378 |
| drug ineffective | 1,999 | 1.9 | 1.8 | 946 |
| dizziness | 727 | 1.9 | 1.7 | 290 |
| off label use | 1,157 | 1.7 | 1.6 | 329 |
| rash | 504 | 1.5 | 1.3 | 76 |
| headache | 715 | 1.4 | 1.3 | 101 |
| fatigue | 860 | 1.4 | 1.3 | 102 |
| nausea | 594 | 1.0 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.